Velaxin, sustained release capsules 75mg 28pcs

Composition

1 tablet contains venlafaxine (in the form of hydrochloride) 75 mg

Pharmacological action

Velaxin has an antidepressant effect.

Indications

• Depression (with or without symptoms of anxiety) both on an outpatient basis and in a hospital.
• Prevention of relapses of depression (with a positive therapeutic effect).

Use during pregnancy and lactation

It is contraindicated during pregnancy and lactation (breastfeeding).

If venlafaxine was used immediately before delivery or shortly before the birth of the baby, it is necessary to take into account the possibility of developing withdrawal syndrome in the newborn.

Contraindications

Hypersensitivity, concomitant use of MAO inhibitors, severe renal impairment (glomerular filtration rate of 18 s), age under 18 years (safety and efficacy for this age group have not been proven), pregnancy or suspected pregnancy, lactation period (there are insufficient data from controlled studies).

Side effects

Common symptoms: weakness, fatigue.

From the gastrointestinal tract: decreased appetite, constipation, nausea, vomiting, dry mouth, rarely — hepatitis.

From the side of metabolism: increased serum cholesterol, decreased body weight, sometimes-changes in the results of laboratory tests of liver function, hyponatremia, syndrome of insufficient secretion of antidiuretic hormone.

From the cardiovascular system: arterial hypertension, hyperemia of the skin, postural hypotension, tachycardia.

From the central nervous system: unusual dreams, dizziness, insomnia, increased excitability, paresthesia, stupor, increased muscle tone, tremor, yawning; sometimes-apathy, hallucinations, muscle spasms, serotonin syndrome, rarely-epileptic seizures, manic reactions, as well as symptoms resembling neuroleptic malignant syndrome.

From the genitourinary system: ejaculation disorders, erections, anorgasmia, dysuric disorders (mainly difficulties at the beginning of urination); sometimes-decreased libido, menorrhagia, urinary retention.

From the sensory organs: accommodation disorders, mydriasis, visual impairment; infrequently-impaired taste sensations.

From the skin: sweating; sometimes-photosensitivity reactions; rarely-erythema multiforme, Stevens-Johnson syndrome.

From the hematopoietic system: sometimes-hemorrhages in the skin (ecchymosis) and mucous membranes, thrombocytopenia; rarely-prolongation of bleeding time.

Interaction

Incompatible with MAO inhibitors.

Reduces the AUC of indinavir by 28% and its Cmax by 36% (the clinical significance of the established phenomenon is unknown).

Increases the anticoagulant effect of warfarin.

Increases the effect of ethanol on psychomotor reactions.

When taken orally, it reduces the total clearance of haloperidol by 42%, increases its AUC by 70% and Cmax by 88%.

Cimetidine suppresses the first-pass metabolism of venlafaxine and has no effect on the pharmacokinetics of O-desmethylvenlafaxine. In most patients, only a slight increase in the overall pharmacological activity of venlafaxine and O-desmethylvenlafaxine is expected (more pronounced in elderly patients and in patients with impaired liver function).

It does not affect the pharmacokinetics of imipramine and 2-OH-imipramine, but the AUC, Cmax and Cmin values of desipramine increase by 35%, and the AUC of 2-OH-desipramine increases by 2.5 – 4.5 times.

Increases the AUC of risperidone by 32%, but does not significantly affect the total pharmacokinetic profile of the active components – risperidone plus 9-hydroxyrisperidone (the clinical significance of this phenomenon is unknown).

It does not interact with lithium preparations and also with drugs metabolized by the CYP3A4, CYP1A2 and CYP2C9 systems (including alprazolam, caffeine, carbamazepine, diazepam).

It does not affect the plasma concentration of drugs with a high degree of protein binding.

How to take, course of use and dosage

Velaxin is taken orally, during meals.

The recommended starting dose is 75 mg daily.

Overdose

Symptoms (often occurs when taking ethanol at the same time): dizziness, decreased blood pressure, ECG changes (prolongation of the Q-T interval, bundle branch block, QRS dilation), sinus and ventricular tachycardia or bradycardia, impaired consciousness (from drowsiness to coma), convulsions and death.

Treatment-symptomatic; monitoring of ECG and vital organ functions; at the risk of aspiration, vomiting is not recommended; washing (if overdose has occurred recently, or symptoms of overdose persist); activated charcoal. The effectiveness of forced diuresis, dialysis, hemoperfusion and blood transfusion has not been proven; specific antidotes are unknown.

Special instructions

Discontinuation of Velaxin: as with other antidepressants, abrupt discontinuation of venlafaxine therapy, especially after high doses of the drug, may cause withdrawal symptoms, and therefore it is recommended to gradually reduce the dose before discontinuing the drug.

The length of time required to reduce the dose depends on the size of the dose, the duration of therapy, and the individual sensitivity of the patient.

Form of production

Tablets

Storage conditions

The drug should be stored in a dry place protected from light at a temperature of not more than 25 C.

Shelf life

5 years

Active ingredient

Venlafaxine

Conditions of release from pharmacies

By prescription

Dosage form

long-acting capsules

Description

For adults as directed by your doctor

Indications

Depression